Paul Yook is 10% at Novus Therapeutics, Inc. (NVUS). They have made 1 open-market trade across 1 company since 2019, most recently 2019-04-30.
CIK 0001735029
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVUS | 1,065,867 | $15.6M |
Shares reported on the most recent Form 4, priced at the 2019-05-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVUS | SELL | 2019-04-30 | 2019-05-02 | $2.70 | $540 | -18.9% | -41.9% | -69.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.